Miltefosine interactions

Food & lifestyle

• food

  Moderate

  Antagonism

  Administration of miltefosine with food may help reduce gastrointestinal adverse effects such as nausea, vomiting, abdominal pain, and diarrhea.

  What to do: Miltefosine should be administered with meals to help improve gastrointestinal tolerance. Patients should be advised to contact their physician if they develop severe or persistent vomiting or diarrhea, and to drink plenty of fluids to help prevent dehydration and kidney injury.

  1 source

  1. "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc (2014):

Conditions

Conditions in which Miltefosine needs care, as documented in this source.

• Sjogren-Larsson Syndrome

  Major

  The use of miltefosine is contraindicated in patients with Sjogren-Larsson syndrome. Miltefosine undergoes metabolic cleavage in hepatocytes to release choline. The fatty alcohol-containing fragment of miltefosine is then oxidized to palmitic acid, which enters the metabolism of fatty acids. However, this oxidation is blocked in patients with Sjogren-Larsson syndrome, who have a genetic defect in fatty aldehyde dehydrogenase activity.

  1 source

  1. "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc (2014):

• Kidney Diseases

  Moderate

  Elevations in serum creatinine were observed in clinical trials of miltefosine for the treatment of cutaneous, mucosal, and visceral leishmaniasis. Patients with serum creatinine or BUN levels at least 1.5 times the upper limit of normal were excluded from clinical trials. The pharmacokinetics of miltefosine have not been studied in patients with renal dysfunction; caution is recommended. Renal function should be monitored weekly during therapy and for 4 weeks after completion of therapy. Abdominal pain, nausea, vomiting, and diarrhea are common side effects of miltefosine; patients should be advised to drink plenty of fluids to avoid dehydration (and, thus, the risk of kidney injury) and to seek medical attention if these gastrointestinal side effects are persistent or severe.

  1 source

  1. "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc (2014):

• Liver Diseases

  Moderate

  Elevations in liver transaminases (ALT, AST) and bilirubin were observed in clinical trials of miltefosine for the treatment of visceral leishmaniasis. Patients with serum ALT or AST levels at least 3 times the upper limit of normal and bilirubin levels at least 2 times the upper limit of normal were excluded from clinical trials. The pharmacokinetics of miltefosine have not been studied in patients with liver dysfunction; caution is recommended. Liver transaminases (ALT, AST) and bilirubin should be monitored during therapy.

  1 source

  1. "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc (2014):

• Thrombocytopenia

  Moderate

  Thrombocytopenia has been reported during treatment of visceral leishmaniasis, including with miltefosine. Therapy with miltefosine should be administered cautiously in patients with preexisting thrombocytopenia. Platelet counts should be monitored during therapy for visceral leishmaniasis.

  1 source

  1. "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc (2014):